These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31208737)

  • 1. [Ustekinumab].
    Jullien D; Staumont-Salle D;
    Ann Dermatol Venereol; 2019; 146(6-7):497-502. PubMed ID: 31208737
    [No Abstract]   [Full Text] [Related]  

  • 2. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.
    Kurzeja M; Rudnicka L; Olszewska M
    Am J Clin Dermatol; 2011 Apr; 12(2):113-25. PubMed ID: 21348542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of inhibition of interleukin-12/23 by ustekinumab on the expression of leptin and leptin receptor in human THP-1 macrophages.
    Voloshyna I; Mounessa J; Carsons SE; Reiss AB
    Clin Exp Dermatol; 2016 Apr; 41(3):308-11. PubMed ID: 26095599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Guselkumab].
    Montaudié H;
    Ann Dermatol Venereol; 2019; 146(6-7):515-519. PubMed ID: 31200928
    [No Abstract]   [Full Text] [Related]  

  • 5. Spotlight on ustekinumab in moderate to severe plaque psoriasis.
    Croxtall JD
    Am J Clin Dermatol; 2012 Apr; 13(2):135-7. PubMed ID: 22201419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
    Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ustekinumab does not increase tuberculosis risk: Results from a national database in South Korea.
    Cho SI; Kang S; Kim YE; Lee JY; Jo SJ
    J Am Acad Dermatol; 2020 May; 82(5):1243-1245. PubMed ID: 31866266
    [No Abstract]   [Full Text] [Related]  

  • 8. A Case of Severe Transaminase Elevation Following a Single Ustekinumab Dose with Remission After Drug Withdrawal.
    Lovero R; Losurdo G; Mastromauro M; Castellaneta NM; Mongelli A; Gentile A; Di Leo A; Principi M
    Curr Drug Saf; 2018; 13(3):221-223. PubMed ID: 30027852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
    Baerveldt EM; Onderdijk AJ; Kurek D; Kant M; Florencia EF; Ijpma AS; van der Spek PJ; Bastiaans J; Jansen PA; van Kilsdonk JW; Laman JD; Prens EP
    Br J Dermatol; 2013 May; 168(5):990-8. PubMed ID: 23278632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risankizumab (Skyrizi) for psoriasis.
    Med Lett Drugs Ther; 2019 Jun; 61(1573):81-83. PubMed ID: 31170118
    [No Abstract]   [Full Text] [Related]  

  • 11. Ustekinumab for chronic plaque psoriasis.
    Bartlett BL; Tyring SK
    Lancet; 2008 May; 371(9625):1639-40. PubMed ID: 18486724
    [No Abstract]   [Full Text] [Related]  

  • 12. Ustekinumab poised to enter the psoriasis market.
    Schmidt C
    Nat Biotechnol; 2008 Dec; 26(12):1317-8. PubMed ID: 19060851
    [No Abstract]   [Full Text] [Related]  

  • 13. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
    J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study.
    Gniadecki R; Bang B; Sand C
    Br J Dermatol; 2016 May; 174(5):1145-6. PubMed ID: 26522308
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of tumor necrosis factor-α, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis.
    Takamura S; Takahashi A; Inoue Y; Teraki Y
    J Dermatol; 2018 Sep; 45(9):1130-1134. PubMed ID: 30004583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of ustekinumab for the treatment of psoriatic arthritis.
    López-Ferrer A; Laiz A; Puig L
    Expert Opin Drug Saf; 2017 Jun; 16(6):733-742. PubMed ID: 28441904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis.
    Zhou H; Hu C; Zhu Y; Lu M; Liao S; Yeilding N; Davis HM
    J Clin Pharmacol; 2010 Mar; 50(3):257-67. PubMed ID: 19934030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The analysis of the therapeutic potential of ustekinumab in psoriasis vulgaris treatment.
    Wcisło-Dziadecka D; Grabarek B; Kruszniewska-Rajs C; Strzałka-Mrozik B
    Dermatol Ther; 2019 May; 32(3):e12843. PubMed ID: 30693647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of ustekinumab on expression of STAT1, STAT3, STAT4, SOCS2, and IL17 in patients with psoriasis and in a control.
    Grabarek B; Krzaczyński J; Strzałka-Mrozik B; Wcisło-Dziadecka D; Gola J
    Dermatol Ther; 2019 Sep; 32(5):e13029. PubMed ID: 31330078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translating the Science of Psoriasis.
    Gordon KB
    Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S64. PubMed ID: 27526392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.